Chronic wounds affect 12-15% of patients with diabetes and are associated with a drastic decrease in their quality of life. Here, we demonstrate that purified mature naive B220
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/IgM
1 /IgD 1 B cells improve healing of acute and diabetic murine wounds after a single topical application. B cell treatment significantly accelerated acute wound closure by 2-3 days in wild-type mice and 5-6 days in obese diabetic mice. The treatment led to full closure in 43% of chronic diabetic wounds, as compared to only 5% in saline-treated controls. Applying equivalent numbers of T cells or disrupted B cells failed to reproduce these effects, indicating that live B cells mediated pro-healing responses. Topically applied B cell treatment was associated with significantly reduced scar size, increased collagen deposition and maturation, enhanced angiogenesis, and increased nerve growth into and under the healing wound. b-III tubulin1 nerve endings in scars of wounds treated acutely with B cells showed increased relative expression of growth-associated protein 43. The improved healing associated with B cell treatment was supported by significantly increased fibroblast proliferation and decreased apoptosis in the wound bed and edges, altered kinetics of neutrophil infiltration, as well as an increase in TGF-b and a significant reduction in MMP2 expression in wound granulation tissue. Our findings indicate that the timeline and efficacy of wound healing can be experimentally manipulated through the direct application of mature, naive B cells, which effectively modify the balance of mature immune cell populations within the wound microenvironment and accelerate the healing process.
Effective and versatile technologies that facilitate acute and chronic wound healing remain a current unmet medical need. In the United States alone, chronic wounds affect an estimated 6.5 million patients, and numbers are expected to grow due to a sharp rise in the worldwide incidence of diabetes and obesity.
1 Cellular and tissue-based treatments that can simultaneously modulate inflammation in the wound microenvironment and promote regenerative responses have recently become a focus of wound care therapy development. 2 In healthy skin, wound healing is divided into four integrated and tightly regulated phases: hemostasis, inflammation, proliferation, and tissue remodeling. 3 Immune cells infiltrate the wound in a specific and predictable order, with neutrophils and macrophages associated with the inflammation phase, and lymphocytes associated with the proliferation and remodeling phases. 4 Chronic wounds are thought to become locked in the inflammatory stage of wound healing, 5 with exaggerated proteolysis in the wound 6 Moreover, the hypoxic conditions of the chronic wound bed degrade beneficial growth factors, preventing the progression toward the establishment of granulation tissue and extracellular matrix (ECM) 3 and full healing. The role of lymphocytes in wound healing, particularly that of B cells, has received little attention. 4 However, recent studies indicate that B cells can act as powerful modulators of tissue regeneration. 7 In addition to their potential to differentiate into antibody-producing plasma cells, B cells can efficiently present antigens to T cells and modulate local immune responses through secretion of pro-and anti-inflammatory cytokines. 8 Interestingly, purified B lymphocytes applied exogenously to a lesion were demonstrated to support recovery. B cells isolated from bone marrow and directly inserted into sites of ischemic cardiac injury in a rat model increased cardiac function and tissue repair, performing better than CD1171 hematopoietic stem cells (HSCs). 9 Studies that examined the impact of B cells in injury also describe beneficial effects on tissue healing. Splenectomized mice, in which the majority of mature B lymphocytes were removed, show delayed wound healing after skin lesions, while systemic reintroduction of isolated B cells rescued the wound healing phenotype. 10 An investigation using CD19-deficient animals suggested that hyaluronic acid within wounds may function as an endogenous ligand for toll-like receptor 4 (TLR-4) on the surface of B lymphocytes, triggering enhanced secretion of interleukin (IL)-6, IL-10, and transforming growth factor (TGF)-b, in a CD19-dependent manner. 11 These cytokines could in turn promote the production of growth factors within the tissue, aiding the healing process. In femoral fracture healing in mice, a system characterized by scarless regeneration, B cells massively infiltrated the callus region and actively promoted proliferative regeneration through secretion of osteoprotegerin. 12 We hypothesized that the introduction of relatively large numbers of B cells (approximately 80,000 cells/mm 3 ), which are typically present only in low numbers (approximately 100 cells/mm 3 ) and are associated with late, proliferative stages of wound healing, could accelerate and support tissue repair. Here, we show for the first time, to our knowledge, that isolated mature naive B cells can accelerate skin wound closure and improve the quality of the regenerated tissue when applied topically onto the wound bed at the time of injury or after wound chronicization in validated mouse models of diabetic and non-diabetic acute and chronic skin ulcers. B cell treatment was associated with reduced scarring and improved collagen deposition. Accelerated healing was supported by increased proliferation of wound fibroblasts in conjunction with decreased levels of apoptosis in the wound bed and edges and pro-regenerative modulation of cytokines and matrix metalloproteinases (MMPs). Acceleration of wound healing was not observed following the application of disrupted B cells, viable T cells, or HSCs.
MATERIALS AND METHODS
Mouse models
Wound healing studies were conducted in 7-to 9-week-old male wild-type C57Bl6/J mice and 8-to 65-week-old male B6.BKS(D) -Lepr db /J mice (Jackson Laboratories, Bar Harbor, ME). Male C57Bl6/J, B6.BKS(D) -Lepr db /J, and FVB-Tg(CAG-luc,-GFP) L2G85Chco/J (all from Jackson Laboratories) were used as isogeneic donors for B and T cell isolation. Animals were maintained under standard laboratory care conditions, at temperatures ranging between 20 and 23 8C, under a 12 hours : 12 hours light : dark cycle, with ad libitum access to food and acidified water.
Lymphocyte isolation
Mouse spleens were collected in ice cold EasySep buffer (STEMCELL Technologies Inc., Vancouver, BC, Canada) containing 2% fetal bovine serum (FBS) and 1 mM ethylenediaminetetraacetic acid in phosphate-buffered saline (PBS). Spleens were dissociated mechanically through a 40 mm cell strainer and the splenocyte suspension was processed for negative B or T cell selection through immunomagnetic separation and retention of nontarget cells, using commercially available cell isolation kits (STEM-CELL Technologies, Inc.) according to the manufacturer's instructions. HSC isolation was performed through positive selection and immunomagnetic separation using CD117 MicroBeads, a MiniMACS separator, and an MS column (Miltenyi Biotec, Inc., Auburn, CA).
Flow cytometry analysis
To assess cell viability after the isolation procedure, the cells were washed and resuspended in PBS, then stained using a Zombie UV fixable viability kit according to the manufacturer's instructions (BioLegend, Inc.). The stained cells were washed and resuspended in PBS containing 1% FBS and 0.01% sodium azide (RICCA Chemical, Arlington, TX), blocked with FcR blocking reagent (Miltenyi Biotec, Inc.) at 10 ml/10 6 cells, then incubated with the following primary antibodies for 30 minutes at 4 8C: FITCconjugated rat anti-mouse IgM (clone RMM-1), Brilliant Violet 605-conjugated rat anti-mouse IgD (clone 11-26c.2a), Brilliant Violet 421-conjugated rat anti-mouse CD19 (clone 6D5), APC-conjugated rat anti-mouse CD45R/B220 (clone RA3-6B2), PE-conjugated rat antimouse CD22 (clone OX-97), PE/Cy7-conjugated rat antimouse CD23 (clone B3B4), Brilliant Violet 510-conjugated rat anti-mouse CD24 (clone M1/69), APC/Cy7-conjugated rat anti-mouse TER-119/erythroid cells (clone TER-119), Brilliant Violet 711-conjugated rat anti-mouse CD3 (clone 17A2), Brilliant Violet 785-conjugated hamster anti-mouse CD11c (clone N418), PE/Dazzle 594-conjugated rat anti-mouse CD117/c-Kit (clone 2B8) (all from BioLegend, Inc.), BUV395-conjugated hamster antimouse CD69 (clone H1.2F3), APC-R700-conjugated rat anti-mouse CD138 (clone 281-2) (all from BD Biosciences, San Jose, CA). The cells were subsequently analyzed on an LSRFortessa X-20 flow cytometer (BD Biosciences) equipped with 355 nm, 405 nm, 488 nm, 561 nm, and 640 nm laser lines. For each sample, at least 50,000 events were collected for analysis. Data were analyzed using FlowJo software, version 10.2 (TreeStar, Inc., Ashland, OR).
Wound model and quantitation of healing
Full-thickness excisional wounds through the dorsal skin were induced as described previously. 13 Briefly, mice were anesthetized with a cocktail of ketamine (100 mg/kg) and xylazine (10 mg/kg), and the dorsal skin was shaved and depilated. Analgesia was provided preoperatively with 0.08 mg/kg buprenorphine injected subcutaneously. The dorsal skin was tented and a 5-mm biopsy punch was passed through the skin fold, creating two symmetrical wounds on each side of the back. Each wound had an initial area of approximately 20 mm 2 . Silicone splints with a square 14 mm by 14 mm outer profile and with an inner diameter of 7 mm were attached around the wounds using Vetbond tissue adhesive (3M, Saint Paul, MN). Cell suspensions in PBS or equal volumes of PBS solution alone (saline control) were applied directly onto the wound bed using a manual pipette. Each treated wound received 1.5 3 10 6 B cells or T cells (control) in 25 ml PBS. HSC controls received 12,000 purified HSCs per wound to replicate the maximum detected levels of CD1171 HSC contamination observed in negatively-selected B cell isolates (0.8%). The splinted wounds were then covered with Tegaderm transparent dressing (3M). High resolution photographs of the wounds (0.018 mm/pixel) were collected at regular intervals and the area of the open wound over time, as well as the area of the visible scar at the end point of each study were assessed using ImageJ software (National Institutes of Health, Bethesda, MD). The splint area in each image was used to calibrate the measurements of the wound and to control for parallax error. Analysis of the wound areas was performed by experimenters blinded to the treatment conditions.
Histology
Wound biopsies at the end point of the wound healing time course were collected using a 10-mm biopsy punch and fixed in 4% paraformaldehyde in PBS for 24-48 hours at 4 8C, after which the samples were dehydrated through graded ethanol and xylene washes, and embedded in paraffin. Transverse sections through the wound bed were cut at a thickness of 5 mm, and mounted onto microscopy slides. Serial sections were stained with hematoxylin and eosin and with Masson's trichrome stain for visualizing collagen fibers. Stained slides were digitized at a resolution of 0.25 mm/pixel using an Aperio CS2 scanner (Leica Biosystems, Buffalo Grove, IL). Digitized slides were used for scoring of tissue regeneration and neutrophil infiltration by observers blinded to the treatment conditions. For cellular infiltrate evaluation, a minimum area of 3,500 mm 2 was examined in each wound region (wound bed, wound edge, and distal).
Immunohistochemistry and confocal imaging
Wound biopsies collected at 0 days (intact), 1 day, 4 days, and 16 days postinjury were fixed in 4% buffered paraformaldehyde for 24-48 hours at 4 8C, then cryoprotected in 1 M sucrose solution for another 24-48 hours at 4 8C, and embedded in tissue freezing medium (Electron Microscopy Sciences, Hatfield, PA). Transverse sections through the wound bed were cut at a thickness of 10 mm using a cryostat (Leica Biosystems), and thaw-mounted onto SuperFrost Plus Gold slides (Fisher Scientific, Waltham, MA). For immunohistochemical detection of antigens, sections were washed through three changes of Tris-buffered saline (TBS) pH 7.4, then permeabilized and blocked by incubation for 1 hour at room temperature with TBS containing 5% bovine serum albumin, 5% FBS, and 0.3% Triton X-100. Sections were then incubated overnight at 4 8C with the following primary antibodies diluted in blocking solution: allophycocyanin-conjugated rat anti-mouse CD45R/B220 (clone RA3-6B2; BioLegend, Inc.), phycoerythrinconjugated rat anti-mouse CD31 (clone MEC 13 The sections were washed three times for 7 minutes in TBS and embedded using Fluoromount (Novus Biologicals, Littleton, CO). Antibody controls included incubation of the tissue sections with isotype antibodies and omission of the primary antibody when a secondary antibody was used for visualization. No unspecific signal was detected in the control samples.
Stained tissue sections were imaged using a Zeiss LSM 710 laser scanning microscope (Carl Zeiss, Oberkochen, Germany) equipped with 203, 403, and 633 objectives. Confocal images were taken at a resolution of 0.1-0.7 lm/ pixel and an optical thickness of 0.5-2.2 lm using Zen software (Carl Zeiss).
Image analysis
Photographs of wounds as well as confocal microscopy images were analyzed using standard functions in ImageJ software (National Institutes of Health). In each photograph, the area of the open wound or the surface of the scar, respectively, as well as the area defined by the inner diameter of the silicone splint were measured manually. The known area of the splint was used to convert measurements from pixels to mm 2 . Confocal images were used to assess cell proliferation, apoptosis, angiogenesis, and neuroregeneration. Cells and cell nuclei were quantified in ImageJ either manually, using the "cell counter" function, or semi-automatically, by subtracting background and converting the image to binary, followed by watershedbased image segmentation to isolate discrete particles, which were then quantified using the "analyze particles" function. Cell counts for specific markers were normalized to total cell counts based on DAPI counterstaining. For quantifying continuous structures, tissue fields of view were outlined manually within each image, and threshold values for hue, saturation, and brightness were applied to select optimal intensity windows that unambiguously identified target structures. For quantifying intracellular expression, regions of interest were defined through intensity thresholding of DAPI counterstaining. The total area and mean labeling intensity of the target structures (blood vessels, nerve endings, or cells) was quantified using the "analyze particles" or "measure" functions, and normalized to the area of the analyzed region of interest. Images used for immunolabeling quantification were collected using identical confocal settings. All analyses were performed by observers blinded to the experimental conditions.
Micro-PET/CT imaging
Isolated splenic B cells were incubated for 3 hours at 37 8C with protamine-conjugated 89 Zr Feraheme nanoparticles 14 at a concentration of 100 mg/ml iron. This incubation time was previously determined to be sufficient for labeling the majority of the B cells in suspension (data not shown). To remove unbound nanoparticles, the cells were centrifuged for 5 minutes at 500 3 g and resuspended in fresh PBS three times, after which the cells were finally resuspended in PBS at a concentration of 100,000 cells/ml. Approximately 2 million B cells in 20 ml of PBS, comprising 20 mCi of total radioactivity, were applied to the wound on the right dorsal side of the animal as described above, while the contralateral wound received an equal volume of PBS. The mice were imaged at regular intervals using an eXplore Vista micro-PET-CT imaging system (GE Healthcare, Chicago, IL). At the end point of the studies, the animals were euthanized and tissue samples from the treated wound site, the control wound, lymph nodes on each side of the body, the spleen, liver, and muscle were collected for measuring residual radioactivity using a 2480 WIZARD 2 gamma counter (Perkin Elmer, Waltham, MA).
IVIS imaging
Splenic B cells were isolated from mice homozygous for the CAG-luc-eGFP L2G85 transgene, which show widespread expression of firefly luciferase and enhanced green fluorescence protein under the CAG promoter (Jackson Laboratories). Approximately 2.2 million luciferaseexpressing B cells in PBS were applied to the wound on one side, as described above, while the contralateral wound received an equal volume of PBS. The mice were imaged using an IVIS Lumina II system (Caliper Life Sciences, Hopkinton, MA) on the day of the surgery and at regular intervals thereafter for a total of 4 weeks. For each imaging session, anesthesia was induced using 3% isoflurane in oxygen and maintained using 1 L/minute of 2-3% isoflurane throughout the imaging session. To visualize luciferase activity, 50 ml of 30 mg/ml aqueous D-luciferin solution (Regis Technologies, Inc., Morton Grove, IL) was injected subcutaneously proximal to the injury site at least 5 minutes before imaging. At the end of the studies, the animals were euthanized and tissue biopsies from the treated wound and the contralateral (control) wound were collected and processed for immunohistochemistry as described above.
Statistical analysis
The statistical significance of differences between experimental groups and/or measures was assessed using one-way, two-way, or two-way repeated-measures ANOVA followed by post hoc multiple comparisons using the Bonferroni or Tukey method. Two-way ANOVA with one within-subjects factor (cell type) and one between-subjects factor (genotype; n 5 3 animals each, values were averaged across three technical replicates) was used for flow cytometry data. Two-way ANOVA with treatment type or dosage as between-subjects factor (n 5 5-30 animals per condition, pooled within genotype across experimental replicates as available) and time point as within-subjects factor was used for the analysis of timed in vivo wound healing studies. Histological evaluations of scar quality were analyzed using either one-way ANOVA with treatment as the main factor, or two-way ANOVA with treatment as between-subjects factor and scoring criterion as within-subjects factor. Immunohistochemistry data (n 5 3-11 images from independent tissue sections collected from 3 to 5 animals per condition) were analyzed using two-way ANOVA with one betweensubjects factor (treatment) and one within-subjects factor (time point, region, or marker), two-way ANOVA with two between-subjects factors (treatment-region combination and time point), or Holm-Sidak method with alpha 5 0.05 and without assuming a consistent SD. All reported descriptive statistics are estimated marginal means 6 standard error of the mean. All statistical analyses were conducted using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA).
Study approval
All animal procedures were performed following the Public Health Service Policy on Humane Care of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Massachusetts General Hospital. All efforts were made to reduce the number of animals used and to minimize animal suffering.
RESULTS
Characterization of B cells isolated from the spleen of wild-type (WT) and diabetic (db/db) animals
After negative immunomagnetic selection, the majority of the isolated cells (85-92%) were CD45R/B220 Table S2 ).
A single topical application of enriched mature naive B cells significantly accelerates wound closure after acute injury in WT and db/db animals To determine the optimal dosage of B cells for application onto wounds, a dose response study was performed in WT mice using 0.1 3 10 6 , 0.5 3 10 6 , 1.5 3 10 6 , 5 3 10 6 , or 10 3 10 6 B cells per 20 mm 2 wound (Supporting Information Fig. S2 ). An application of 1.5 3 10 6 B cells was selected as the lowest dosage that showed a significant acceleration of wound closure (F (72, 400) 5 2.92, p < 0.0001). To examine the effect of B cell treatment on acute wounds, 1.5 3 10 6 negatively-selected B cells, T cells, or only saline were applied onto splinted fullthickness excision lesions immediately after injury. Purified HSCs at a dosage equivalent to the maximum estimated numbers of HSC contamination in negatively selected B cell isolates (0.8%) were included as an additional control in diabetic animals. In WT animals, B cell-treated wounds closed 2-3 days earlier than either saline or T cell-treated controls, showing significantly reduced open wound areas after day 2 postinjury (F (16, 360) 5 4.747, p < 0.0001). No significant differences were observed between the saline control and the T cell treatment ( Figure 1A and B). All wounds eventually closed fully within the observed time interval, with the visible scar size being significantly smaller in B cell-treated wounds ( Figure 2F ). In diabetic animals, the regenerative effect of B cells was more pronounced, with B cell-treated wounds closing 5-6 days earlier than either saline-treated, HSC-treated or T cell-treated controls, and showing significantly reduced areas after day 6 postinjury (F (52, 780) 5 9.184, p < 0.0001). B cells isolated from healthy or diabetic animals performed equally well ( Figure  1C) . Notably, approximately 64% of the 50 wounds treated with saline, HSCs, or T cells progressed toward a chronic ulcer phenotype, remaining >50% open up to day 34 post-injury, with only 0.5% of the ulcers fully closed. By contrast, only 7.9% of the 38 B cell-treated wounds remained >40% open by this time point, with 50% of the wounds fully closed ( Figure 1C and D) .
We hypothesized that the pro-regenerative effects of B cell application are cell-mediated, and not simply based on the immediate action of molecular factors contained within the cells. To test this hypothesis, wounds were treated either with whole B cells in suspension, or with an equivalent number of B cells that were first disrupted through sonication. Live B cell treatment accelerated wound closure by approximately 3 days (F (16, 136) 5 3.446, p < 0.0001), performing significantly better than either equivalent numbers of lysed B cells, or saline control ( Figure 1E and F) .
B cell treatment improves the quality of tissue repair
At the end of the wound healing time course, the wounded areas were excised and evaluated histologically for indicators of tissue regeneration, including overall width and thickness of the scar tissue, collagen deposition and maturation, angiogenesis, and nerve growth (see Supporting Information Table S3 for parameters and scoring system). In WT animals, acute B cell treatment was associated with improved tissue regeneration and a smaller scar surface (Figure 2) . B cell-treated wounds scored significantly better than wounds treated with saline or T cells (F (2, 55) 5 18.34, p < 0.0001). This benefit was largely due to improved patterning of collagen deposition, with fibers distributed in a reticulated pattern resembling the structure Figure 2F ).
In db/db mice, treatment with B cells derived from the spleen of either WT or diabetic syngeneic animals led to reduced scar area and more compact scar tissue, with less vacuolization and inflammatory cell infiltration (Figure 3 ). Wounds treated with either WT or db/db B cells scored significantly better than wounds treated with saline or T cells (F (3, 62) 5 12.42, p < 0.0001). This improvement was supported by the deposition and maturation of collagen fibers, enhanced angiogenesis, neuroregeneration, defined as the growth of new nerve endings under and into the scar tissue, and significantly reduced scar width (F (21, 434) 5 4.353, p < 0.0001; Figure 3F ). As in WT animals, collagen fibers were deposited in a reticulated pattern in the scars of wounds treated with B cells as compared to large parallel bundles observed in controls, particularly after treatment with WT B cells ( Figure 3C Figure 3G ).
B cell treatment reactivates proliferative healing in chronic diabetic skin ulcers
To assess whether B cell application can reinitiate healing in a chronic ulcer, wounds were generated on the dorsal skin in obese diabetic mice and treated with saline dressing only. After 10 days, all wounds were still open, and most showed rounded, nonproliferative edges typical of chronic ulcers. 15 At this time point, the wounds were treated with WT-derived B cells or saline. A rapid reduction of over 50% in the area of the open wound was observed 4 days after B cell application (Figure 4) , and the treated wounds maintained a significant advantage in the closure rate up to 30 days (F (6, 174) 5 15.97, p < 0.0001). Over the course of the study, 43% of the wounds treated with B cells closed fully, as compared to only 5% of the saline treated wounds. At 30 days postinjury, wounds with at least 50% of the initial surface still open were subjected to a second application of either B cells or saline control ( Figure 4C) . B cell treatment again showed a positive effect as compared to saline (F (1, 13) 5 6.435, p < 0.05), with a 10% reduction in the open area of the treated wounds. This effect was most pronounced at 4 days post B cell application and was maintained at 8 days (F (2, 26) 5 3.889, p < 0.05). B cell application enhanced cell proliferation and migration in the edges of the treated wounds, as indicated by the change in the wound edge morphology from rounded to flat, forming an epithelial tongue which extended toward the wound bed (Figure 4B and D) .
B cells derived from aged db/db mice can accelerate wound healing in aged diabetic animals
To assess the efficacy of B cells that were subjected to prolonged exposure to a diabetic hyperglycemic environment, cells were isolated from aged (15-month-old) obese db/db mice and applied onto acute wounds in 6-to 15-month-old obese db/db mice. Results indicated that the B cell treatment prevented the initial inflammatory enlargement of the wounds often observed in saline-treated controls, and furthermore led to a significant acceleration of wound closure (F (7, 84) 5 21.45, p < 0.0001) and reduced scar size in all animals examined (n 5 7; Figure 4G and H).
Exogenous B cells localize to the wound bed and remain viable up to 2 weeks after application
To examine whether exogenously applied B cells are retained within or migrate away from the site of application, B cells were labeled with 89 Zr-protamine-conjugated Feraheme nanoparticles before application onto wound beds. Positron emission tomography combined with computed tomography (PET/ CT) scanning of the whole body showed that the signal remained well-localized within the wound bed up to 13 days ( Figure 5 ). Some loss of signal at the wound site may occur due to cell death and subsequent diffusion of released nanoparticles. Indeed, when free nanoparticles were applied to the wound bed in the absence of B cells, diffusion of the signal occurred rapidly, leading to an apparent loss of signal intensity at the injury site and increased activity in other organs, including lymph nodes and spleen, by day 14 postapplication (Figure 5A-C) . To examine in situ survival of the introduced cells, luciferase-expressing B cells were applied onto the wound bed and the mice were imaged over 24 days. Light emission indicating active enzymatic activity within the applied cells strongly declined after day 6, and reached undetectable levels by day 14 ( Figure 5D-E) . These results indicate that the exogenous B cells have a limited life span of up to 2 weeks in situ within the wound bed.
Immunohistochemical analysis of tissue sections collected from the wound site confirmed that the number of B220 1 B cells in the wound bed and edges was significantly elevated after exogenous application (F (1, 58) 5 37.31, p < 0.0001). The introduced B cells became well integrated into the newly formed granulation tissue (Supporting Information Fig. S3A-B) . B220
1 cells were detected in significantly higher numbers in B cell-treated wounds as compared to saline-treated controls at 1 and 4 days postapplication (F (3, 58) 5 7.987, p < 0.001), but this difference was no longer statistically significant at 17 days (p 5 0.353; Supporting Information Fig. S3C) .
B cell application is associated with increased fibroblast proliferation, reduced apoptosis in the wound bed and edges and a pro-regenerative wound molecular microenvironment
To examine the mechanism for the accelerated wound healing observed following B cell application, treated and control biopsies collected at 24 hours and 4 days after injury and treatment were labeled against cleaved caspase-3 and Ki67, as markers of apoptosis or cell proliferation, respectively. Counts were normalized to the overall cell density based on DAPI counterstaining. Results showed a significant decrease in the relative numbers of apoptotic cells in wounds treated with B cells at the time of injury (F (1, 48) 5 15.67, p < 0.001; Figure 6A -C and G). At the same time points, cell proliferation was significantly increased in B cell-treated tissues as compared to saline controls (F (1, 48) 5 23.59, p < 0.0001; Figure 6D-F and H) .
When distinct regions of the wound were analyzed independently 4 days after injury and treatment, high numbers of B cells were associated with increased cell proliferation and reduced apoptosis, particularly in the wound bed and edges ( Figure 7B ). In agreement with results indicating limited persistence of exogenous cells at the wound site, proliferating Ki67 1 /B220 1 B cells were never observed in situ ( Figure 7A and C) . Virtually all mitotic cells were fibroblasts, identified by immunolabeling with a monoclonal antibody raised against mouse fibroblasts, and they were localized proximally to the B cells ( Figure 7A and D). These results indicate that the B cell-mediated acceleration of wound healing is associated with a skewing of the apoptosis-proliferation balance in the wound bed and edges, leading to a net addition of cells.
B cell treatment was associated with multiple changes in the molecular microenvironment of the wound bed. At 4 days after injury, a significant increase in TGF-b was observed in cells of the granulation tissue in B cell-treated wounds (F (2, 26) 5 7.783, p < 0.01; Supporting Information Fig. S4A-B) . No significant changes in expression were observed for other growth factors such as fibroblast growth factor 2 (FGF2), or in the anti-inflammatory cytokine IL-10 at this time point (Supporting Information Fig. S4E ). Conversely, a significant decrease in the expression of MMP2, a major proteolytic enzyme, within and around the cells in the wound bed was observed in B cell-treated wounds as compared to saline controls (F (1, 18) 5 45.97, p < 0.001; Supporting Information Fig. S4C-D) . No significant change was observed in the expression of MMP8 between B cell-treated and control wounds (Supporting Information Fig. S4F ). These results further support the view that the application of B cells induces discrete changes in the wound microenvironment that accelerate wound closure.
B cell application accelerates the dynamics of neutrophil infiltration into the wound
To examine the dynamics of inflammatory cell infiltration at the wound site, as related to B cell application, tissue sections from wound biopsies collected at 24 hours, 4 days, 10 days, and 16 days after injury were stained with Figure 4 . B cell treatment reactivates proliferative wound healing in chronic diabetic skin ulcers and in aged diabetic animals. (A) Wounds were treated with 2 million B cells in saline or saline control 10 days after injury (arrow), and the area of the wound was measured over 30 days. A pronounced reduction in the area of the open wound was observed in wounds treated with B cells at 4 days postapplication and this was maintained throughout the course of the study. Significance was assessed using two-way repeated-measures ANOVA, followed by Tukey's multiple comparisons test. **** p < 0.0001; * p < 0.05. (B) Example of a wound illustrating static wound edge morphology at day 10 (arrow), which is temporarily reversed by B cell treatment at day 14, before it reverts to a static rounded-edge phenotype characteristic of chronic ulcers by day 30. hematoxylin and eosin and the numbers of neutrophils were analyzed in the wound bed, wound edge and the periphery of the wound biopsy (Supporting Information  Fig. S5 ). Baseline numbers of neutrophils in the intact skin as well as distally to the wound were very low at 1.1 3 10 6 and 1.6 3 10 6 cells/mm 3 (Supporting Information Fig. S5A ). In wounds treated with B cells, significantly increased numbers of neutrophils were observed in the wound bed at early time points, particularly at 24 hours when they reached 45 (6 1.1) 3 10 6 cells/mm 3 as compared to 29 (6 2.8) 3 10 6 cells/mm 3 (p < 0.0001) in saline-treated controls and, somewhat less pronounced, at 4 days after the injury, decreasing rapidly at later time points. By contrast, saline-treated controls showed less acute neutrophil infiltration early after injury, but the rate of reduction in neutrophil numbers over time was 2.5 times slower than in B cell-treated wounds, as indicated by the linear regression slope (Supporting Information  Fig. S5B ). By 10 days postinjury, the difference in neutrophil numbers reversed, with saline-treated wounds having on average 19 (6 1.8) 3 10 6 cells/mm 3 while B cells treated wounds showed only 11 (6 3) 3 10 6 cells/mm 3 . Moreover, in the wound edge, the peak of neutrophil infiltration was observed at 1 day in B cell-treated wounds with 19 (6 2.6) 3 10 6 cells/mm 3 , but at 10 days in salinetreated controls with 11.5 (6 1.9) 3 10 6 cells/mm 3 . These results suggest an overall acceleration of the acute response to injury in animals treated with B cells.
B cell treatment enhances regeneration of vasculature and nerve fibers in the scar tissue
To investigate whether B cell application alters the trophic environment of the wound and affects long-term regenerative phenomena, including angiogenesis and neuroregeneration, tissue sections collected from healed scar tissue that had been treated with either B cells or saline were labeled with anti-CD31 and anti-b-III tubulin antibodies to visualize endothelial cells and neurites, respectively (Figure 8) . Quantification of the area covered by immunolabeling with either of these markers showed that acute B cell application was associated with significant increases in the extent of angiogenesis and neuroregeneration within the scar tissue at day 16 postinjury, as compared to salinetreated controls (F (1, 17) 5 20.66, p < 0.001; Figure 8C ). These results confirm a broad-impact pro-regenerative effect of exogenous B cells, which appears to lead to a shift in the trophic properties of the wound microenvironment, even at long intervals after injury.
Moreover, nerve endings that grew under and within the scar tissue of wounds that were treated with B cells at the time of injury showed significantly increased expression of growth-associated protein 43 (GAP43), an established marker of axonal regeneration 16 (Supporting Information  Fig. S6 ). Regenerating nerve endings were not immunopositive for the neuropeptide substance P, and thus were not peptidergic C fibers, 17 suggesting that the enhanced neurite growth was not associated with detrimental increases in nociceptive sensitivity in the scar tissue (Supporting Information Fig. S6 ).
DISCUSSION
This study demonstrates for the first time, to our knowledge, that the progression of wound healing in the skin can be positively manipulated by altering the balance of a mature immune cell population, specifically B cells, within the wound microenvironment. While the roles of neutrophils and macrophages in wound healing are welldocumented, little is known regarding B cells in this context. Some studies report that no B cells can be found at the site of a lesion, 18 while others describe only very low cell numbers infiltrating the wound bed. 10 In the present study, B cells were detected at above-baseline levels at 4 days after injury in saline-treated control wounds, and persisted at that level up to 17 days postinjury in WT mice. These results are in agreement with other reports demonstrating the presence of B cells in the wound bed at 3 and 7 days after a skin lesion, 11 and indicate that B cells do normally infiltrate the wound tissue, albeit in low numbers. Direct application of exogenous B cells shifted the proportion of this lymphocyte population present in the wound bed and the time after the injury when they become locally abundant.
While no previous study has examined the impact of direct B cell transfer into the wound environment, several studies indicate that circulating B cells play an active role in wound healing. 10 It has been hypothesized that B cell production of IgG1 immunoglobulins aids in the opsonization of dead cells at the injury site, facilitating their clearance by macrophages. 10 Mice deficient in the B cell-specific antigen CD19 show impaired wound healing, while overexpression of CD19 on B cells accelerates wound closure. 11 Interestingly, ECM components can induce CD19-dependent TLR signaling in the B cells localized in the wound, which in turn induces the expression of key cytokines such as IL-6, IL-10, and TGF-b.
11
These factors can directly reduce inflammation and promote the proliferation of fibroblasts and keratinocytes, for example through the TGF-b pathway, 19 but they can also act indirectly, by regulating skin expression of cytokines and growth factors. Indeed, in the present study, the application of B cells onto acute wounds led to an initial increase in the numbers of neutrophils infiltrating into the wound bed, followed by a rapid decrease. The rate of neutrophil depletion in the granulation tissue of the wound bed was 2.5-fold faster than in saline-treated controls, supporting the hypothesis of an overall acceleration in the timeline of wound healing stages. Interestingly, in CD19 -/-knockout mice, both reduced neutrophil infiltration as well as delayed wound healing have been reported. 11 An investigation that used direct exogenous application of isolated B lymphocytes at the site of cardiac ischemia showed that intramyocardial injection of B cells into injured myocardium preserved cardiac function by preventing cardiomyocyte apoptosis and stimulating local cell proliferation. 9 These results are consistent with the findings of the present study, where B cell application to the wound bed at the time of the lesion was associated with significantly reduced apoptosis and enhanced fibroblast proliferation at 1 and 4 days after injury and treatment. This effect of B cells may be mediated via b-catenin, an important regulator of fibroblast behavior during the proliferative phase of dermal wound repair. 19 The results of the present study point to a complex multi-modal modulatory effect of exogenously added B cells in the context of wound healing. In granulation tissue at 4 days postinjury, B cell treatment was associated with an increase in the expression of major activating growth factors such as TGF-b, which at this stage is observed predominantly in fibroblasts and wound macrophages. At the same time, the expression of MMP2, a protease whose upregulation is an indicator of chronic wounds, 20 was reduced in B cell-treated wounds as compared to saline controls. Together, these observations support the notion that the presence of B cells can reduce the proteolytic characteristics of the wound microenvironment, preventing tissue degradation, and at the same time can promote a shift toward a more trophic milieu that can enhance fibroblast proliferation in the granulation tissue.
Application of B cells at the time of injury in the present study was associated with a significant increase in the number of capillaries and nerve endings within the area of the scar over two weeks later. During wound healing, angiogenic capillary sprouts invade the fibrin/ fibronectin-rich wound clot and organize into a microvascular network throughout the granulation tissue. 21 Neutrophils infiltrating at early stages of wound healing have been previously shown to promote angiogenesis, 22 making the significantly increased neutrophil infiltration at the wound site observed at early time points in B cell-treated wounds a potential indirect mechanism for increased vascularization. Moreover, while B cells are known to secrete some proangiogenic factors upon stimulation, such as TGF-b, 11 they likely support angiogenesis indirectly, by inducing the secretion of cytokines and growth factors in neighboring fibroblasts and keratinocytes, as observed in the wound bed. Similarly, B cell therapy creates a permissive microenvironment for nerve fiber regrowth. Histological analysis showed that in WT mice, approximately 64% of the wounds (9/14) treated acutely with B cells showed pronounced innervation and cutaneous nerve growth under the scar tissue at 16 days postinjury, as compared to only 20% of the wounds (6/30) treated with saline. Interestingly, the converse effect is well documented, as denervation of a skin domain slows the rate of wound healing in that area by reducing the inflammatory infiltrate, including T and B lymphocytes. 23 These results point to a significant reciprocal neuroimmune crosstalk in the wound microenvironment as observed in lymphoid organs, 24 which could be used as a mechanism for regulating neuroregeneration in the context of injury. 25 Such an effect will be especially relevant for the treatment of diabetic wounds and ulcers, where main obstacles to healing include vasculopathy and neuropathy. 1, 26 Importantly, B cells isolated from aged diabetic mice and applied onto wounds in aged db/db mice, all of which showed pronounced hyperglycemia, still had unaltered capacity for promoting wound healing, providing a promising option for the development of autologous immunotherapies for patients with diabetes.
In summary, we demonstrate that the topical application of mature, minimally manipulated B lymphocytes can alter the progression of acute and chronic wounds in a spatiotemporally localized manner. Taken together, these data support the Figure 6 . B cell application at the time of injury alters the rates of apoptosis and cell proliferation in the wound bed and edges. (A-C) Confocal images of transverse sections through the wound edge collected at 4 days postinjury are shown immunolabeled against the apoptosis marker activated caspase-3. Cell nuclei are counterstained with DAPI. While very few caspase-3-positive cells can be found in intact skin (A), injury induces high levels of apoptosis (B), which is significantly reduced in wounds treated with B cells (C). Scale bars, 100 mm. (D-F) Confocal images of transverse sections through the wound edge at 4 days postinjury immunolabeled against the cell proliferation marker Ki67. Cell nuclei were counterstained with DAPI. Cell proliferation in the intact skin is mostly restricted to stem cells in the hair follicles and the epidermis (D). Injury induces a regenerative response, elevating the numbers of proliferating cells which invade the wound bed (E), and this response appears greatly amplified in wounds treated with B cells (F). gr 5 granulation tissue in the wound bed. Scale bars, 100 mm. (G-H) Quantitative analysis of apoptotic caspase-3-immunopositive cells (G) and proliferating Ki67-immunopositive cells (H) in the wound bed and edges at 1 and 4 days postinjury. Scale bars, 100 mm. At least three fields from three distinct sections were analyzed per animal; at least three animals were analyzed per condition and time point. Statistical significance was assessed by two-way ANOVA, followed by Tukey's multiple comparisons test. ** p < 0.01; *** p < 0.001; **** p < 0.0001. [Color figure can be viewed at wileyonlinelibrary .com] view that the experimental manipulation of the numbers and the timing of B cells arriving at the wound site affects multiple aspects of the inflammatory and proliferative stages of wound healing, modulating and abbreviating the inflammatory phase and inducing a pro-regenerative molecular milieu in the wound bed. These results support the further development of a novel and promising autologous B cell-based immunotherapy applicable to difficult-to-treat acute and chronic wounds including, most notably, diabetic foot ulcers. cell density, assessed in confocal fields of transverse sections through the scar tissue at day 16 postinjury and treatment (n 5 3 animals per condition; three fields from independent sections were analyzed for each animal). Analyses were performed using WT animals. Statistical significance was assessed using multiple t-tests followed by Holm-Sidak correction for multiple comparisons. ** p < 0.01; *** p < 0.001. [Color figure can be viewed at wileyonlinelibrary.com]
